Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its Chief Medical Officer, Phil Pang, M.D., Ph.D., will present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on October 6, 2021, at 11:30 a.m. PT / 2:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page and archived for 30 days. Vir focuses on immunological solutions for infectious diseases, with a pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
- None.
- None.
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on Wednesday, Oct. 6, at 11:30 a.m. PT / 2:30 p.m. ET.
A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.
The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investors website, in addition to following the Company’s press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
FAQ
When is Phil Pang's presentation at the Guggenheim Conference?
Where can I watch Vir Biotechnology's presentation live?
What topics will Vir Biotechnology discuss at the conference?
What is the significance of the Guggenheim Conference for Vir Biotechnology?
How can investors stay updated on Vir Biotechnology's announcements?
